NEUROLOGY INFUSION REFERRAL FORM



PATIENT INFO	RMATION			PRESCRIBER II	NFORMAT	ION			
ast Name	First Name		DOB	Name of Contact Sending	Referral		Title		
Gender	Last 4 SSN		Primary Language		mail Referral Con		tact Email		
Address			1	Office Phone	ax	Office Fax			
City State		ZIP	Practice / Facility Name	ractice / Facility Name					
Email				Address					
Home Phone Work Phone			Cell Phone	City	City		ZIP		
Primary Contact Method (check one)	☐ Cell Phone☐ Text☐ En☐ DO NOT CO	nail 🗆 Primar		Prescriber Name / Specialty	Prescriber Name / Specialty				
Primary Caregiver/Alt Contact Name (If applicable)				Prescriber State License #	Prescriber State License #				
Caregiver/Alt Contact Email Careg		giver/Alt Contact Phone	NPI#	NPI #		Medicaid UPIN #			
INSURANCE IN	IFORMATI	ON							
Insurance Provider			Plan ID #	Eligible for Medicare (check one)	□ Yes □ No	If yes, list Med	dicare #		
BIN#:	PCN#:		RX Group#:	Prescription Card (check one)	□ Yes	If yes, list carr	ier		
isured's Name		Relationship to Patient	Please include a	a copy of the front and back of insurance co					
CLINICAL INFO	ORMATION			Trease include a	topy or the n		in or insurance e		
Prescription Type	□ Naïve/New □Therapy Res □ Existing Trea	start	Therapy Start Date	Patient Height (cm/in)	Patient Weigh	nt (kg/lbs)	Date Obtained		
Sample/Starter Product Provided?	If yes, Provide		Date Sample Provided	l i	Ship to Address ☐ Home ☐ Prescriber's Office ☐ Other (please list)				
□ Yes □ No Allergies □ NKDA □ Drug Allergies (please list) Therapies Tried and Failed (please list medications)					ICD-10 Codes D69.3 Immune Thrombocytopenic Purpura D525.82 Stiff-man Sydrome G55 Multiple Sclerosis G60.3 Idiopathic Progressive Neuropathy G61.0 Gullain-Barre Syndrome G61.81 Chronic Inflammatory Demyelinating Polyneuritis G62.89 Multifocal Motor Neuropathy G70.00 Myasthenia Gravis without (acute) exacerbation				
Concurrent Medications				_ □G □L □N □N	□ G70.01 Mysthenia Gravis with (acute) exacerbation □ L10.0 Pemphigus Vulgaris □ M33.20 Polymyositis organ involvement unspecified □ M33.90 Dermatopolymyositis organ involvement unspecifi □ Other				

PRESCRIPTIONS

Patient Last Name			Patient First Name	DOB	DOB	
PRESCRIPTION	INFOR	MATION				
MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS	
□ Immune Globulin	□SC □IV □IM	grams grams	☐ 1 mg/kg/hr for first 30 minutes then increase every 30 minutes to a max rate of 6m/kg/hr not to exceed 300 ml/hr	□1 month □3 months	□ 1 year	
□Lemtrada	□IV	□ 12 mg/day	☐ Initial Dose – 12 mg/day over 4 hours for 5 consecutive days ☐ Maintenance Dose – 12 mg/day IV over 4 hours for 3 consecutive dates 12 months after initial dose		□ 1 year	
□Ocrevus	□IV	□ 300 mg/10 mL vial	□ Starter Dose – Infuse 300 mg iv over no less than 2.5 hours on day 1 and day 15 □ Maintenance Dose – Infuse 600 mg iv over no less than 3.5 hours every 6 months		□1 year	
□Tysabri	□IV	□ 300 mg in 100 mLs NaCl 0.9%	□ Infuse over 60 minutes every 6 months		□ 1 year	
□ Normal Saline □ D5W	□IV	□ 3 mL □ 5 mL	☐ Before and after infusion	□ 1 month □ 3 months	□ 1 year	
☐ Heparin 10 units/mL ☐ Heparin 100 units/mL	□IV	□3 mL □5 mL	□ After infusion	□1 month □3 months	□ 1 year	
□ Diphenhydramine	□ PO □ IV □ IM	□ 25 mg □ 50 mg □	☐ After infusion ☐ PRN Allergic Reaction:	□With each infusion	□ 1 year	
☐ Acetaminophen	□РО	□325 mg □500 mg □650 mg □1 gm	□ Pre-Med:	□With each infusion	□ 1 year	
□Epinephrine	□IM □SQ	☐ Adult 1:1000, 0.3 mL (>30kg/>66lbs) ☐ Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	□ PRN Anaphylaxis □ Repeating Dose:	□ Once	□1 year	
□ Other:						
□ Vascular Access Method	□periphe	ral □central □other:				
					Total RXs	
needles, syringes, ancillary su	ipplies and n	nedical equipment necessary to estab	ion and assess general status and response to therapy. Dispense 1 month plish access and administer medication. Prescription to include all necessa nalf of patient for administration in office.		lies	
Patient Support Prog	rams: Ple	ase have patient sign and c	date to enroll in pharmaceutical company assisted sup	port progra	m.	
Patient Signature			Date Account Manager			
Prescriber Authorizat	tion (No s	tamps. Signature and date	must be completed in prescriber's handwriting.)			
Prescriber Signature			// Date			
Supervising Physician Signature (Dispense as Written)			// Date			

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.